Soleno targets 1,000 new VYKAT XR patient start forms in next 9-12 months while expanding into new rare disease indications
Source: SeekingAlpha
2026-02-26 04:28:20 ET
More on Soleno Therapeutics
- Soleno Therapeutics, Inc. (SLNO) Q4 2025 Earnings Call Transcript
- Soleno Therapeutics: Why I'm Staying On The Sidelines
- Seeking Alpha’s Quant Rating on Soleno Therapeutics
- Historical earnings data for Soleno Therapeutics
- Financial information for Soleno Therapeutics
Read the full article on Seeking Alpha
For further details see:
Soleno targets 1,000 new VYKAT XR patient start forms in next 9–12 months while expanding into new rare disease indications
Soleno Therapeutics Inc.
NASDAQ: SLNO
SLNO Trading
-8.84% G/L:
$33.52 Last:
2,079,152 Volume:
$36.44 Open:
SLNO Latest News
March 13, 2026 06:28:00 pm
Notice to Long-Term Investors of Soleno Therapeutics, Inc. (SLNO): Grabar Law Office Investigates Claims on Your Behalf
March 13, 2026 02:45:00 pm
Deadline Approaching: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
SLNO Stock Data
$2,184,386,717
45,438,681
1.25%
73
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
